Reprogramming macrophages to treat cardiovascular disease

We develop cutting-edge RNA therapeutics to treat cardiovascular disease. By leveraging advanced delivery systems and ML-directed RNA sequence design, we build RNAs that selectively transform cardiac macrophages, in vivo, to treat disease with unprecedented safety and efficacy.